The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

The Washington Post editorial board argued a federal judge's ruling against congressional Medicaid restrictions on abortion ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

The Trump administration is preparing a five-year pilot program that could allow Medicare and Medicaid to cover expensive GLP ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

UnitedHealth Group says it is cooperating with federal criminal and civil investigations involving its market-leading ...